Covid vaccine play 🚀🚀🚀
VBIV CEO Baxter said on a feb 5 2021 podcast that human trials were to begin in the next couple of weeks for their single dose monovalent covid vaccine vbi-2902, which received $56 Million from Canada to produce a vaccine. Today moderna announced forecasted sales of ~$18 Billion just from covid vaccine sales. Once VBi announces initiation of human trials for the ph1/2 study planned in Canada, I’m expecting a sizeable move to the upside.
Cup and handle - handle retraced to FIBO 618 retrace net which is a nice area to see bounce. I see potential to test The previous high of $6.98 as perceptive advisors did not sell any shares after loading bigly sub-$1 prior to that run which was over 1000% incl trade for them. This shows they expect SP to move significantly higher or fhey would have sold a percentage to re add on dips after that massive run.
With all the catalysts in 2021, GBM treatment with eVLP , SCI-b-vac and hepB therapeutic, pan-corona vaccine and this single dose vaccine, I see no reason why this can’t be double digits by year end.
Please like and follow! 🚀🚀🚀🚀
Disclosure: not investment advice as I am not a financial advisor. This information is to be used for educational purposes only.
Cup and handle - handle retraced to FIBO 618 retrace net which is a nice area to see bounce. I see potential to test The previous high of $6.98 as perceptive advisors did not sell any shares after loading bigly sub-$1 prior to that run which was over 1000% incl trade for them. This shows they expect SP to move significantly higher or fhey would have sold a percentage to re add on dips after that massive run.
With all the catalysts in 2021, GBM treatment with eVLP , SCI-b-vac and hepB therapeutic, pan-corona vaccine and this single dose vaccine, I see no reason why this can’t be double digits by year end.
Please like and follow! 🚀🚀🚀🚀
Disclosure: not investment advice as I am not a financial advisor. This information is to be used for educational purposes only.
Related publications
Disclaimer
The information and publications are not meant to be, and do not constitute, financial, investment, trading, or other types of advice or recommendations supplied or endorsed by TradingView. Read more in the Terms of Use.